Clinical Trial

Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation

Study acronym: DUAL - PE
Completed
View on ClinicalTrials.gov →
Summary
Premature ejaculation is a common sexual condition that can cause distress for men and their partners. Different treatments are available, but some men do not respond well to standard therapies. This study was designed to evaluate whether injecting botulinum toxin type A into two areas of the penis and surrounding muscles can help delay ejaculation in men with lifelong premature ejaculation. Participants were randomly assigned to receive either botulinum toxin injections or placebo injections. The study evaluated ejaculation time, sexual satisfaction, and quality of life over a follow-up period of six months. Safety and possible side effects were also monitored during the study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-17.
Trial Details
NCT Number NCT07426640
Lead Sponsor Al Mouwasat Hospital
Conditions Premature (Early) Ejaculation
Enrollment 150 participants
Start Date 2021-11-01
Primary Completion 2024-11-30 (estimated)
Study Completion 2024-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-17